Relaxing the US coronavirus lockdown: move slowly, stay nimble

Diagnostics, treatment, and vaccine progress could allow near-normal distancing and nonessential business recovery by mid-2021, Morningstar says.

Morningstar Analysts

12 May 2020

Mentioned: Gilead Sciences Inc (GILD)

COVID-19, the disease caused by SARS-CoV-2 (coronavirus), has spread across the globe, and as we enter May, several countries and US states are testing ways to relax lockdowns and provide some relief for the economy.

While we don't think US states will follow federal guidelines for reopening, we expect the transition to be gradual and that they will quickly reverse any moves that lead to a spike in new cases.

Diagnostic testing has improved more rapidly than we anticipated, to around 250,000 a day, and we think a combination of continued social distancing (masks and 2m rule), steady improvement to 800,000 tests per day by the end of the year (which facilitates contact tracing and surveillance), broader availability of Gilead Sciences' remdesivir, and potential targeted antibodies and vaccines by the end of the year in high-risk populations should allow visits to nonessential businesses (restaurants, salons, and retailers) to recover to 30 per cent below prepandemic levels by the end of the year (from a trough at around 65 per cent below in March).

Broader availability of Gilead Sciences' remdesivir, and potential targeted antibodies and vaccines by the end of the year in high-risk populations should allow visits to nonessential businesses, Morningstar strategists say

Infection rate to stay below 10pc

Our new base-case scenario assumes that less than 10 per cent of the US population is infected by the end of 2020, with a 0.7 per cent death rate, as improving levels of testing help control the spread of the disease.

Remdesivir's recent emergency use authorisation (EUA) in severely ill COVID-19 patients is a turning point, but efficacy to date does not look strong enough on its own to justify relaxing lockdowns.

That said, we project US$2 billion in peak sales in 2021, assuming an eventual US price (after donated supplies) of around $500 per treatment.

Vaccine progress has accelerated from an already rapid pace: Moderna, Johnson & Johnson, Pfizer, and AstraZeneca could all receive EUAs by the end of the year.

Assuming that at least two succeed, potential broad availability (billions of doses) would allow near-normal distancing measures by mid-2021.

CORONAVIRUS

COVID19

KAREN ANDERSEN

REMDESIVIR

US ECONOMY

US EQUITIES

AUTHOR

Morningstar Analysts
.

	Last	$ Change	% Change
Gilead Sciences Inc GILD	$92.57	1.48	+1.62%

© 2024 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This report has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or New Zealand wholesale clients of Morningstar Research Ltd, subsidiaries of Morningstar, Inc. Any general advice has been provided without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide at www.morningstar.com.au/s/fsg.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782.